NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts